Industry Insight
Discovery Technology
Analytical Laboratory Technology
Biopharma
Manufacturing
Delivery Systems
Ingredients, Formulation and Finishing
Bioprocessing
View our other publications with free access to extensive archives
  To print this article:
Existing subscribers please log in:
 
  USER NAME  
  PASSWORD  
   Or select

Or become a subscriber
 
 
 

RabMAbs as an Alternative Source of Therapeutic Leads

Properties such as high binding affinity and specificity, the ability to recognise novel epitopes and ease of humanisation make rabbit monoclonal antibodies (RabMAbs) an attractive target for the development of therapeutic antibodies.

By Guo-Liang Yu at Epitomics, Inc (March 2010)

Keywords: RabMAbs, alternative, therapeutic leads, novel epitopes, rabbid monoclonal antibodies, platforms, high binding affinity, surrogate antibody, humanising

    View full article    |    Back to Biopharma section




Advair,Flovent,VentolinSymbicort,Serevent,FlonaseAstelin Rhinocort
IPTonline © 2004 The Pharmaceutical Technology Journal | Terms and Conditions | info@iptonline.com | UK Contacts |
Providing a platform of communication on new ideas, developments and innovations | UK Tel No. +44 20 77243456 | Back to top of page |